Effect of infant viral respiratory disease on childhood asthma in a non-industrialized setting.

asthma helminths rhinoconjunctivitis viral infections wheeze

Journal

Clinical and translational allergy
ISSN: 2045-7022
Titre abrégé: Clin Transl Allergy
Pays: England
ID NLM: 101576043

Informations de publication

Date de publication:
Aug 2023
Historique:
revised: 22 06 2023
received: 24 01 2023
accepted: 25 07 2023
medline: 26 8 2023
pubmed: 26 8 2023
entrez: 26 8 2023
Statut: ppublish

Résumé

There are limited data from non-industrialized settings on the effects of early life viral respiratory disease on childhood respiratory illness. We followed a birth cohort in tropical Ecuador to understand how early viral respiratory disease, in the context of exposures affecting airway inflammation including ascariasis, affect wheezing illness, asthma, and rhinoconjunctivitis in later childhood. A surveillance cohort nested within a birth cohort was monitored for respiratory infections during the first 2 years in rural Ecuador and followed for 8 years for the development of wheeze and rhinoconjunctivitis. Nasal swabs were examined for viruses by polymerase chain reaction and respiratory symptom data on recent wheeze and rhinoconjunctivitis were collected by periodic questionnaires at 3, 5, and 8 years. Stools from pregnant mothers and periodically from children aged 2 years were examined microscopically for soil-transmitted helminths. Atopy was measured by allergen skin prick testing at 2 years. Spirometry, fractional exhaled nitric oxide measurement, and nasal washes were performed at 8 years. Associations between clinically significant respiratory disease (CSRD) and wheezing or rhinoconjunctivitis at 3, 5, and 8 years were estimated using multivariable logistic regression. Four hundred and twenty six children were followed of which 67.7% had at least one CSRD episode; 12% had respiratory syncytial virus (RSV)+CSRD and 36% had rhinovirus (RHV)+CSRD. All-cause CSRD was associated with increased wheeze at 3 (OR 2.33 [95% confidence intervals (CI) 1.23-4.40]) and 5 (OR: 2.12 [95% CI 1.12-4.01]) years. RHV+CSRD was more strongly associated with wheeze at 3 years in STH-infected (STH-infected [OR 13.41, 95% CI 1.56-115.64] vs. uninfected [OR 1.68, 95% CI 0.73-3.84]) and SPT+ (SPT+ [OR 9.42, 95% CI 1.88-47.15] versus SPT- [OR 1.92, 95% CI 0.84-4.38]) children. No associations were observed between CSRD and rhinoconjunctivitis. CSRD was significantly associated with childhood wheeze with stronger associations observed for RHV+CSRD in SPT+ and STH-infected children.

Sections du résumé

BACKGROUND BACKGROUND
There are limited data from non-industrialized settings on the effects of early life viral respiratory disease on childhood respiratory illness. We followed a birth cohort in tropical Ecuador to understand how early viral respiratory disease, in the context of exposures affecting airway inflammation including ascariasis, affect wheezing illness, asthma, and rhinoconjunctivitis in later childhood.
METHODS METHODS
A surveillance cohort nested within a birth cohort was monitored for respiratory infections during the first 2 years in rural Ecuador and followed for 8 years for the development of wheeze and rhinoconjunctivitis. Nasal swabs were examined for viruses by polymerase chain reaction and respiratory symptom data on recent wheeze and rhinoconjunctivitis were collected by periodic questionnaires at 3, 5, and 8 years. Stools from pregnant mothers and periodically from children aged 2 years were examined microscopically for soil-transmitted helminths. Atopy was measured by allergen skin prick testing at 2 years. Spirometry, fractional exhaled nitric oxide measurement, and nasal washes were performed at 8 years. Associations between clinically significant respiratory disease (CSRD) and wheezing or rhinoconjunctivitis at 3, 5, and 8 years were estimated using multivariable logistic regression.
RESULTS RESULTS
Four hundred and twenty six children were followed of which 67.7% had at least one CSRD episode; 12% had respiratory syncytial virus (RSV)+CSRD and 36% had rhinovirus (RHV)+CSRD. All-cause CSRD was associated with increased wheeze at 3 (OR 2.33 [95% confidence intervals (CI) 1.23-4.40]) and 5 (OR: 2.12 [95% CI 1.12-4.01]) years. RHV+CSRD was more strongly associated with wheeze at 3 years in STH-infected (STH-infected [OR 13.41, 95% CI 1.56-115.64] vs. uninfected [OR 1.68, 95% CI 0.73-3.84]) and SPT+ (SPT+ [OR 9.42, 95% CI 1.88-47.15] versus SPT- [OR 1.92, 95% CI 0.84-4.38]) children. No associations were observed between CSRD and rhinoconjunctivitis.
DISCUSSION CONCLUSIONS
CSRD was significantly associated with childhood wheeze with stronger associations observed for RHV+CSRD in SPT+ and STH-infected children.

Identifiants

pubmed: 37632244
doi: 10.1002/clt2.12291
pmc: PMC10408584
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e12291

Subventions

Organisme : Wellcome Trust
ID : 088862/Z/09/Z
Pays : United Kingdom

Informations de copyright

© 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.

Références

J Allergy Clin Immunol. 2007 May;119(5):1105-10
pubmed: 17353039
World Allergy Organ J. 2016 Jun 27;9:20
pubmed: 27386040
Front Immunol. 2021 Mar 16;12:635935
pubmed: 33796103
Arch Dis Child. 1992 Apr;67(4):482-7
pubmed: 1580676
Pediatr Allergy Immunol. 2022 Mar;33(3):e13741
pubmed: 35338734
Clin Infect Dis. 2021 Nov 2;73(9):e2493-e2499
pubmed: 32592580
Thorax. 2000 Aug;55 Suppl 1:S2-10
pubmed: 10943631
PLoS One. 2017 Feb 9;12(2):e0171687
pubmed: 28182741
Br Med J (Clin Res Ed). 1982 Jun 5;284(6330):1665-9
pubmed: 6805648
PLoS Negl Trop Dis. 2021 Dec 16;15(12):e0010050
pubmed: 34914687
J Allergy Clin Immunol. 2017 Oct;140(4):895-906
pubmed: 28987219
Nat Rev Dis Primers. 2020 May 28;6(1):44
pubmed: 32467581
Arch Dis Child. 1997 Apr;76(4):315-9
pubmed: 9166022
Eur Respir J. 2019 Nov 14;54(5):
pubmed: 31515399
Lancet. 2022 May 28;399(10340):2047-2064
pubmed: 35598608
J Allergy Clin Immunol. 2022 Jun;149(6):2139-2152
pubmed: 34968529
Influenza Other Respir Viruses. 2022 Jan;16(1):24-33
pubmed: 34432362
Clin Exp Allergy. 2008 Nov;38(11):1769-77
pubmed: 18547322
Expert Rev Anti Infect Ther. 2011 Sep;9(9):731-45
pubmed: 21905783
Infect Immun. 2018 Nov 20;86(12):
pubmed: 30249744
Am J Respir Crit Care Med. 2005 Jan 15;171(2):137-41
pubmed: 15516534
Vaccines (Basel). 2020 Apr 26;8(2):
pubmed: 32357557
Am J Respir Crit Care Med. 2011 Sep 1;184(5):602-15
pubmed: 21885636
N Engl J Med. 2016 Jan 7;374(1):62-72
pubmed: 26735994
BMC Pediatr. 2012 Sep 13;12:147
pubmed: 22974166
Lancet Respir Med. 2018 Apr;6(4):257-264
pubmed: 29500030
Ann Allergy Asthma Immunol. 2019 Oct;123(4):352-358
pubmed: 31276807
Lancet Respir Med. 2020 Aug;8(8):795-806
pubmed: 32763206
Am J Respir Crit Care Med. 2021 Sep 1;204(5):523-535
pubmed: 33961755
J Allergy Clin Immunol. 2022 Jun;149(6):1960-1969
pubmed: 34996616
Lancet. 1999 Aug 14;354(9178):541-5
pubmed: 10470697
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Front Allergy. 2021 Aug 05;2:687073
pubmed: 34888545
Am J Respir Crit Care Med. 2008 Oct 1;178(7):667-72
pubmed: 18565953
Int J Epidemiol. 2015 Oct;44(5):1517-27
pubmed: 24990475
PLoS Negl Trop Dis. 2021 Nov 19;15(11):e0009972
pubmed: 34797823
Allergy. 2007 Apr;62(4):385-93
pubmed: 17362249
N Engl J Med. 2013 May 9;368(19):1791-9
pubmed: 23656644
Allergy. 2021 Sep;76(9):2765-2775
pubmed: 33745189
Am J Med. 1968 Mar;44(3):377-89
pubmed: 5641301

Auteurs

Jessica Atwell (J)

Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Martha Chico (M)

Fundacion Ecuatoriana Para la Investigacion en Salud, Quito, Ecuador.

Maritza Vaca (M)

Fundacion Ecuatoriana Para la Investigacion en Salud, Quito, Ecuador.

Andrea Arévalo-Cortes (A)

Escuela de Medicina, Universidad Internacional del Ecuador, Quito, Ecuador.

Ruth Karron (R)

Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Philip J Cooper (PJ)

Fundacion Ecuatoriana Para la Investigacion en Salud, Quito, Ecuador.
Escuela de Medicina, Universidad Internacional del Ecuador, Quito, Ecuador.
Institute of Infection and Immunity, St George's University of London, London, UK.

Classifications MeSH